NCT04449289 is a Phase 2 clinical trial of Intravenous lidocaine in Pancreatic Cancer, sponsored by Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor.

What drugs are being tested in NCT04449289?

Interventions in NCT04449289: Intravenous lidocaine, Epidural ropivacaine.

What condition does NCT04449289 study?

NCT04449289 studies Pancreatic Cancer.

Is NCT04449289 still recruiting?

NCT04449289 is currently status unknown. Last updated 26 June 2020.

Last reviewed 2020-06-26 · How we verify

NCT04449289

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Influence of Local Anesthetic Administration on the Cancer Recurrence Rate After Pancreatic Oncologic Surgery

Status unknown Phase 2 Last updated 26 June 2020

What this trial tests

Phase 2 trial testing Intravenous lidocaine in Pancreatic Cancer in 100 participants. Status unknown.

Timeline

1 July 2020

Primary endpoint
31 December 2021

31 December 2024

Quick facts

Lead sponsor	Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 July 2020
Primary completion	31 December 2021
Estimated completion	31 December 2024
Sites	1 location across Romania

Drugs / interventions tested

Intravenous lidocaine — full drug profile →
Epidural ropivacaine — full drug profile →

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor

Who can join

Adults 18 to 80, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Study aims to compare the influence of intravenous lidocaine and peridural ropivacaine on postoperative long and short term outcome in patients with pancreatic cancer undergoing surgery. As short term endpoints: postoperative complications and resumption of bowel function. Long term endpoints include: 1 and 3 year recurrence and mortality.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Perioperative Intravenous Lidocaine and Metastatic Cancer Recurrence - A Narrative Review.
Wall TP, Buggy DJ. · · 2021 · cited 29× · PMID 34408981 · DOI 10.3389/fonc.2021.688896
Trial watch: local anesthetics in cancer therapy.
Carnet Le Provost K, Kepp O, Kroemer G, Bezu L. · · 2024 · cited 5× · PMID 38504848 · DOI 10.1080/2162402x.2024.2308940
Anaesthetic Techniques and Strategies: Do They Influence Oncological Outcomes?
Murphy L, Shaker J, Buggy DJ. · · 2023 · cited 3× · PMID 37366886 · DOI 10.3390/curroncol30060403
Anesthetics and Long Term Cancer Outcomes: May Epigenetics Be the Key for Pancreatic Cancer?
Mokini Z, Cama A, Forget P. · · 2022 · cited 1× · PMID 36013569 · DOI 10.3390/medicina58081102

Verify or expand the search:

Other trials of Intravenous lidocaine

Trials testing the same drug.

NCT07089173 — The Effect-site Concentration of Remifentanil Blunting Endotracheal Intubation Responses During Anesthesia Induction Wit · NA · recruiting
NCT06952309 — Intravenous Lidocaine Plus Intratracheal Dexmedetomidine on Postoperative Sore Throat · NA · not yet recruiting
NCT05238506 — Lidocaine VS Hemodynamic, Metabolic and Hormonal Response · Phase 4 · completed
NCT04574947 — Lidocaine And Neuromonitoring in Thyroid Surgery · Phase 4 · completed

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor trials

Trials by the same sponsor.

NCT06216509 — Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements · NA · completed
NCT05474872 — Postoperative Delirium in the ICU Setting of an Eastern European Centre · unknown
NCT05418543 — CH-EUS in Diagnosis of Inoperable Bile Duct Tumors · NA · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04449289 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institutul Regional de Gastroenterologie & Hepatologie Prof. dr. Octavian Fodor
Last refreshed: 26 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04449289.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing